Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 3
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
EGFR L858R
gastric cancer · Monoclonal Antibody
EGFR L858R is flagged as trial selection rising because public trials show inclusion required evidence in 6 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 3
Common snippets: HER2-low | MSI-H | MSI-H
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Medium
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT04168931 | https://clinicaltrials.gov/study/NCT07334431 | https://clinicaltrials.gov/study/NCT07529613 | https://clinicaltrials.gov/study/NCT05608785 | https://clinicaltrials.gov/study/NCT06329973 | https://clinicaltrials.gov/study/NCT05104567